Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Politics : Politics for Pros- moderated -- Ignore unavailable to you. Want to Upgrade?

To: DewDiligence_on_SI who wrote (606149)	8/26/2016 3:01:20 PM
From: D. Long	1 Recommendation Recommended By Sdgla Respond to of 793672

What's at issue in this thread (on government conspiracies) is the FDA's rejection of Teva's application to sell a generic version of Mylan's Epipen—i.e. a product that would be automatically substitutable for Mylan's EpiPen by any pharmacist. Which part of this do you not understand is regulation by the FDA of a fancy needle that effectively prevents competition?

To: DewDiligence_on_SI who wrote (606149)	8/26/2016 3:03:41 PM
From: alanrs	Read Replies (1) \| Respond to of 793672

You know, I'd buy that, and it's true I know nothing about the subject from any prior exposure. However, it is claimed that Mylan has a corner on the market so maybe this product serves a different market than I assumed. Say it's entirely for the government and school market, for people who don't need it but might be called on to administer, taxpayer funded. Maybe in real life anybody with a recurring situation goes to one of the other options, from buying vials and using diabetic disposables to whatever. Why would anybody both to try to meet an "exactly the same" standard when they could go for similar but does the same job, foregoing the 'generic' classification. Or does that run afoul of another government reg. I'm really not into conspiracies, but this one just doesn't make sense without the fat hand of the government being involved, big time. I can only conjecture how, it passes the time of day. ARS

To: DewDiligence_on_SI who wrote (606149)	8/26/2016 3:43:53 PM
From: DMaA	1 Recommendation Recommended By SirWalterRalegh Respond to of 793672

FDA overreach is costing us dearly in many ways. Obviously there's a massive increase in the cost of all health care. Companies supplying the industry have to maintain huge departments of high paid people to deal with the FDA. They don't make anything, they don't invent anything, they don't sell anything. They just keep the bureaucrats from closing down the company. But we also pay through the loss of access to innovative devices. Any innovation is taking place overseas because American companies can't do development with any hope of making a profit in the current regulatory environment. It's costing jobs, it's directly reducing GDP growth. We are not getting good value for the gigantic cost of today's FDA. .